Table 1.
Baseline Characteristics According to Sex
| All Patients (N=16 821) | Men (n=12 514) | Women (n=4307) | P Value | |
|---|---|---|---|---|
| Age, y | n=16 821, 67.9±12.0 | n=12 514, 66.4±11.8 | n=4307, 72.1±11.4 | <0.001 |
| BMI, kg/m2 | n=16 182, 27.4±4.7 | n=12 066, 27.5±4.4 | n=4116, 26.9±5.5 | <0.001 |
| Current smoker | n=16 575, 4488 (27.1) | n=12 335, 3609 (29.3) | n=4240, 879 (20.7) | <0.001 |
| Hypertension | n=16 694, 11 577 (69.3) | n=12 416, 8330 (67.1) | n=4278, 3247 (75.9) | <0.001 |
| Diabetes mellitus | n=16 757, 3893 (23.2) | n=12 464, 2837 (22.8) | n=4293, 1056 (24.6) | 0.014 |
| Hypercholesterolemia | n=16 665, 10 741 (64.5) | n=12 393, 8028 (64.8) | n=4272, 2713 (63.5) | 0.138 |
| Family history of coronary artery disease | n=16 684, 4323 (25.9) | n=12 404, 3159 (25.5) | n=4280, 1164 (27.2) | 0.027 |
| Previous myocardial infarction | n=16 743, 2976 (17.8) | n=12 453, 2425 (19.5) | n=4290, 551 (12.8) | <0.001 |
| Previous PCI | n=16 741, 3989 (23.8) | n=12 449, 3168 (25.4) | n=4292, 821 (19.1) | <0.001 |
| Previous CABG | n=16 759, 1701 (10.1) | n=12 463, 1435 (11.5) | n=4296, 266 (6.2) | <0.001 |
| Previous TIA or stroke | n=16 750, 1237 (7.4) | n=12 456, 914 (7.3) | n=4294, 323 (7.5) | 0.685 |
| Peripheral arterial disease | n=16 738, 1448 (8.7) | n=12 448, 1064 (8.5) | n=4290, 384 (9.0) | 0.413 |
| History of malignancy | n=16 746, 1810 (10.8) | n=12 455, 1303 (10.5) | n=4291, 507 (11.8) | 0.014 |
| Renal failure* | n=16 098, 3329 (20.7) | n=12 008, 2074 (17.3) | n=4090, 1255 (30.7) | <0.001 |
| History of atrial fibrillation/atrial flutter | n=11 845, 1450 (12.2) | n=8810, 1055 (12.0) | n=3035, 395 (13.0) | 0.131 |
| Chronic obstructive lung disease | n=16 747, 1113 (6.6) | n=12 455, 887 (7.1) | n=4292, 226 (5.3) | <0.001 |
| History of spontaneous bleeding | n=16 819, 729 (4.3) | n=12 513, 539 (4.3) | n=4306, 190 (4.4) | 0.762 |
| History of gastrointestinal bleeding | n=16 744, 368 (2.2) | n=12 452, 274 (2.2) | n=4292, 94 (2.2) | 1.000 |
| Left ventricular function (%) | n=15 122, 52.3±13.7 | n=11 261, 51.9±13.5 | n=3861, 53.5±14.0 | <0.001 |
| Hemoglobin before PCI, g/L | n=14 853, 136.54±18.11 | n=11 059, 139.82±17.49 | n=3794, 127.00±16.44 | <0.001 |
| Hemoglobin nadir, g/L | n=14 003, 126.97±20.64 | n=10 358, 130.42±20.04 | n=3645, 117.16±19.10 | <0.001 |
| ARC HBR score | n=16 821, 0.66±0.83 | n=12 514, 0.60±0.80 | n=4307, 0.82±0.86 | <0.001 |
| Clinical indication for PCI | n=16 821 | n=12 514 | n=4307 | <0.001 |
| Stable CAD | 7318 (43.5) | 5426 (43.4) | 1892 (43.9) | 0.521 |
| Unstable angina | 783 (4.7) | 576 (4.6) | 207 (4.8) | 0.586 |
| NSTEMI | 4218 (25.1) | 3056 (24.4) | 1162 (27.0) | 0.001 |
| STEMI | 4502 (26.8) | 3456 (27.6) | 1046 (24.3) | <0.001 |
| Killip class II, III or IV | n=16 780, 2844 (16.9) | n=12 486, 2042 (16.4) | n=4294, 802 (18.7) | <0.001 |
Data are presented as absolute numbers and percentage or mean±SD. ARC indicates Academic Research Consortium; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; HBR, high bleeding risk; NSTEMI, non–ST‐segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST‐segment–elevation myocardial infarction; and TIA, transient ischemic attack.
*
Renal failure: <60 estimated glomerular filtration rate mL/min/1.73 m2, using the Modification of Diet in Renal Disease formula.